Oncology · Follicular LymphomaTrial Updateclinicalmid-term

Study on Clonal Evolution in Follicular Lymphoma by NCI

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/26/2026, 6:31:08 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing study by the National Cancer Institute on clonal evolution in follicular lymphoma is critical as it may reveal new insights into disease progression and treatment responses. These findings could significantly influence future therapeutic strategies and competitive dynamics in the oncology sector. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 24 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should monitor findings from this study to inform the development of new therapies and adjust strategies based on emerging data on disease evolution. The strongest clinical anchor is Clonal Evolution in Follicular Lymphoma (ClinicalTrials.gov), entity match (national cancer institute). In Oncology · Follicular Lymphoma, 5 regulatory and 4 competitive items passed relevance filtering for National Cancer Institute.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer. This study may provide insights into the biology of follicular lymphoma, potentially influencing future treatment strategies and competitive positioning for therapies targeting this disease.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Emerging data from this study may inform regulatory submissions for new treatments, affecting approval timelines and labeling for therapies targeting follicular lymphoma.

Key Risks

Elevated medium regulatory exposure for National Cancer Institute could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Insights from this study could lead to the development of new therapies, potentially impacting market share and revenue for companies involved in treating follicular lymphoma.
Upside for National Cancer Institute may improve if Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Upside for National Cancer Institute may improve if Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.

What Would Change This Assessment

This becomes more urgent if Key milestones include the completion of participant monitoring phases and any published findings on disease progression and treatment responses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Other | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials - 08/27/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Clonal Evolution in Follicular Lymphoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
NCI Trials B7-H3 CAR T Cell Therapy for Refractory Small Cell Lung Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Zanubrutinib Plus Anti-CD20 Shows Promise in R/R Follicular and Marginal Zone Lymphoma Study
Humanexa Signalsmedium relevance
Moderate corpus alignment
Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Single-cell sequencing profiling of intratumoral heterogeneity and immunosuppressive microenvironment in primary thyroid cancer and lymph node metastases.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

National Cancer Institute
follicular lymphoma therapies

Commercial impact

medium

Insights from this study could lead to the development of new therapies, potentially impacting market share and revenue for companies involved in treating follicular lymphoma.

Regulatory impact

medium

Emerging data from this study may inform regulatory submissions for new treatments, affecting approval timelines and labeling for therapies targeting follicular lymphoma.

What to watch

Key milestones include the completion of participant monitoring phases and any published findings on disease progression and treatment responses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.